Home

Deck

TAZMO · 6266 · TSE

Tazmo is a Japanese niche capital-equipment maker for semiconductor and flat-panel display fabs — bonder/debonder tools, wafer-handling robots, slit coaters and PCB plating lines, each priced $600k to $6M per unit and shipped in lumpy batches.

$20
Price
$290M
Market cap
$226M
Revenue (FY2025)
1979
Founded
Traded around $4 in mid-2016, peaked near $30 in April 2024, now $20 — about 5× the decade-ago level in dollars after a 29% retrace as order backlog halved over seven quarters.
2 · The variant perception

FY2026's guided 24% profit drop reads catastrophic — the mechanism is the mix-shift bill for a chiplet-era pivot.

  • The mix swing. Inside Process Equipment (78% of group sales), semiconductor equipment grew 40% to $110M in FY2025 while cleaning collapsed 69% to $11M and the slit coater fell 66% to $5M. Headline operating margin slid from 16.5% to 13.5% because advanced-packaging tools ship at lower per-unit margins than the legacy cleaning recipes they displaced.
  • The Q1 FY2026 print. Revenue -20.6% YoY, operating margin 1.4% against Q1 FY2025's 16.1% (FY2024 peaked at ~22% in Q2-Q3), EPS $0.05 versus the lone analyst estimate near $0.21 — a 4-5× headline miss. Reads as collapse; the mechanism is two product lines being decommissioned while three new ones ramp.
  • The peer comp. SUSS MicroTec — same 13% operating margin, same bonder franchise, roughly 2-3× the revenue base — trades at 37× trailing P/E. Tazmo trades at 13×. The gap is wider than scale alone explains; the residual is the market refusing to credit Tazmo's bonder pipeline.
The bear case treats the mix swing as terminal margin compression. The bull case treats it as the same operating-leverage profile that produced the FY2019 trough before the FY2024 peak.
3 · The cycle, in numbers

Backlog has fallen seven straight quarters; revenue caught up last, and the trough is here.

$126M
Order backlog $298M peak Q1-23
$226M
FY2025 revenue -1.2% YoY
13.5%
Operating margin 16.5% in FY2024
$50M
Free cash flow $28M ex-WC release

Backlog peaked in Q1 FY2023 and led revenue down by three quarters — the cleanest cycle signal this company prints. The headline $50M FCF flatters: strip the work-in-process release and underlying generation is closer to $28M. What would confirm a through-cycle trough: backlog stabilising above $125M for two consecutive quarters and semi-equipment share of Process Equipment crossing 65%.

4 · The re-rating lever

Three bonder tools — TBDB, LAB, DTB — are the path to SUSS-class economics.

  • Product cadence. First LAB unit ships early 2026. DTB demonstration unit completed in FY2026. DTB mass production targeted 2027. If those dates hold, semi-equipment compounds into the chiplet and AI-packaging cycle at SUSS-comparable economics.
  • Slit-coater pivot. Tazmo's #1-share LCD colour-filter coater — a maturing $5M business — is being repositioned as a panel-level-packaging tool and folded into the Semi segment from FY2026. Optionality on PLP at no incremental R&D cost.
  • R&D tells the story. R&D budget guided to $7.5M in FY2026, up 64% in a year operating profit guides down 25%. Management is spending into the pivot, not defending the print.
The setup is not for a TEL multiple. It is whether the SUSS multiple, applied to a cleaner Tazmo mix, supports a 2-3× upside on multiple alone — with no margin expansion required.
5 · What the capex tells you

$44M of FY2026 capex is what management would not approve if the AI-packaging cycle were ending.

  • Capex stepping up 4.7×. FY2025 capex was $10M; FY2026 guidance is $44M — funding an Ibara demonstration plant and TAZMO Vietnam capacity. Long-term borrowings rose ~$5M in Q1 ($30M → $35M) to start funding it. That spend rate is incompatible with the bear case.
  • Maiden buyback. $3.3M repurchased in FY2025 — the first in company history. Net cash sits at $54M, roughly 18% of market cap. Whether buybacks become habitual is the single biggest variable in the five-year compounding case.
  • One yellow flag. A 'Correction of Numerical Data' was filed alongside the FY2025 annual report on 2026-03-23, magnitude undisclosed. The broader forensic file is clean, but the correction landing beside an aggressive capex print earns eyes on the H1 FY2026 disclosure.
Capex and buyback move in opposite directions on the same balance sheet. Management is doing both — a tell that the AI-packaging tape is not over.
6 · Bull & Bear

Lean long, wait for confirmation — the next print decides whether Q1 was the trough or the trend.

  • For. Bonder franchise into chiplet-era packaging trades at a quarter of peer SUSS's multiple on the same margin profile. Maiden buyback and $44M capex commitment signal management conviction the cycle holds.
  • For. Backlog at $126M has held above the $95M bear threshold; Q1 contract liabilities rebuilt to $30M from $23M at year-end — the first sequential rise since the Q1-23 peak, consistent with new orders being booked.
  • Against. Q1 FY2026 operating margin of 1.4% and a 4-5× EPS miss against the only analyst. If H2 FY2026 fails to recover, the multiple compresses toward 8-10× small-cap-specialist territory.
  • Against. Customer concentration in Japan and China; export controls plus Chinese substitution in transfer and EFEM tools are open threats. No services tail to cushion an order pause — when shipments stop, revenue stops.
My view: the SUSS-twin mispricing is real, but the entry is conditional. A Q2 print with sub-5% operating margin and backlog below $95M forces an exit.

Watchlist to re-rate: Q2 FY2026 results mid-August (margin recovery); first LAB unit shipment with a named customer; order backlog stabilising above $125M for two consecutive quarters.